Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.17 (market cap $78.99B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.5 (market cap $26.26B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 3× Royalty Pharma plc Class A Ordinary Shares's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| NGG | RPRX | |
|---|---|---|
Market Cap | $78.99B | $26.26B |
Volume | 740,402 | 2,828,067 |
Sector | Utilities | Health |
52-Week High | $93.93 | $63.96 |
52-Week Low | $73.54 | $36.18 |
Enterprise Value | $137.22B | $33.49B |
Dividend Yield | 4.13% | 1.59% |
Typical Hold Time | — | 6 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
